<DOC>
	<DOCNO>NCT00025675</DOCNO>
	<brief_summary>RATIONALE : Biological therapy gefitinib may interfere growth tumor cell slow growth CNS tumor . PURPOSE : Phase II trial study effectiveness gefitinib treat patient recurrent progressive CNS tumor .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Recurrent Progressive CNS Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gefitinib patient recurrent progressive supratentorial malignant glioma brain spinal meningioma receive enzyme-inducing antiepileptic drug ( EIAEDs ) . ( Phase I study close accrual 09/19/2003 ) . - Determine toxic effect drug patient . - Determine pharmacokinetics drug patient receive EIAEDs . - Determine efficacy drug term 6-month progression-free survival patient . - Determine safety profile phase II dose drug patient . OUTLINE : This multicenter , dose-escalation study . Patients stratify accord concurrent enzyme-inducing antiepileptic drug ( EIAEDs ) ( yes v ) disease type ( phase II ) ( benign meningioma v malignant meningioma v hemangiopericytoma v glioblastoma v anaplastic glioma ) . ( Phase I close accrual 09/19/2003 ) . Patients receive oral gefitinib daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient ( receive EIAEDs ) receive escalate dos gefitinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A minimum 30 patient accrued phase I portion study within 10 month . ( Phase I close accrual 09/19/2003 ) . A total 48 patient accrue phase II portion study within 6-8 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically confirm supratentorial malignant primary glioma Glioblastoma multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix oligoastrocytoma Malignant astrocytoma otherwise specify Histologically confirm radiographically define recurrent progressive brain spinal meningioma , include base skull cavernous sinus meningioma Benign , malignant , atypical May include neurofibromatosis type I II Hemangiopericytoma allow Recurrent progressive disease MRI CT scan Evidence true progressive disease PET thallium scan , MR spectroscopy , surgical documentation require patient receive prior interstitial brachytherapy stereotactic radiosurgery ( target lesion meningioma hemangiopericytoma ) Steroid dosage must stable least 5 day prior scan No limitation number prior surgery , radiotherapy chemotherapy regimen , radiosurgery treatment patient meningioma hemangiopericytoma may include standard external beam radiotherapy , interstitial brachytherapy , gammaknife radiosurgery combination Patients glioma must fail prior radiotherapy Original histology lowgrade glioma allow subsequent confirmation malignant glioma make time recurrence Phase I ( close accrual 09/19/2003 ) : Prior treatment 3 prior relapse patient glioma Phase II : Measurable disease prior surgical resection recurrent progressive disease Prior treatment 2 prior relapse patient glioma PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 8 week Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 120,000/mm^3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT le 1.5 time ULN Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No significant cardiac risk factor within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No gastrointestinal risk factor ( e.g. , active ulcerative colitis ) within past 6 month No active infection No concurrent disease would obscure toxicity dangerously alter drug metabolism No significant medical illness would preclude study No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior interferon thalidomide No concurrent filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics At least 2 week since prior vincristine At least 6 week since prior nitrosoureas At least 3 week since prior procarbazine Endocrine therapy : At least 1 week since prior tamoxifen Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics At least 7 day since prior surgery recurrent progressive tumor recover Other : Recovered prior therapy No prior gefitinib epidermal growth factor receptor inhibitor At least 1 week since prior isotretinoin At least 1 week since prior noncytotoxic agent ( except radiosensitizers ) At least 4 week since prior investigational agent Concurrent lowmolecular weight heparin warfarin deep vein thrombosis pulmonary embolism allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
</DOC>